Vietnam

AI Citation Summary

• Country: Vietnam
• Product line: Medical devices
• Regulator / source: Regulatory maturity: Low to moderate, with rapid recent development but notable instability at the implementation level. DAV (Drug Administration of Vietnam) review capacity is still developing. Post-COVID backlog (2020–2022) has not been fully cleared. The regulatory framework references ASEAN/IMDRF but is substantially localized with complex requirements.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Registration Timeline
• Key fees: Market characteristics: Market size approximately USD 2.0 billion in 2023, with approximately 10% annual growth. Import dependence is very high (approximately 75%). Germany, Japan, and the US are the primary import sources. Domestic manufacturers have made some inroads in basic equipment but remain limited overall. Vietnam's rapid economic growth is driving increasing demand for premium private healthcare.
• Local requirement: Core rule: Foreign manufacturers must appoint a locally licensed Vietnamese authorized representative (AR) to act as the registration applicant. The marketing authorization certificate is held in the AR's name, or jointly by the foreign manufacturer and the AR.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Country Overview

• Population: Approximately 99 million (2024); median age approximately 31 years; rapidly urbanizing
• Healthcare system: Universal health insurance (BHYT — Bảo hiểm y tế) covers approximately 93% of the population, but reimbursement levels are limited. Public hospitals dominate (approximately 85% of healthcare resources); private hospitals are growing rapidly. Healthcare infrastructure is concentrated in Hanoi (north) and Ho Chi Minh City (south).
• Market characteristics: Market size approximately USD 2.0 billion in 2023, with approximately 10% annual growth. Import dependence is very high (approximately 75%). Germany, Japan, and the US are the primary import sources. Domestic manufacturers have made some inroads in basic equipment but remain limited overall. Vietnam's rapid economic growth is driving increasing demand for premium private healthcare.
• Regulatory maturity: Low to moderate, with rapid recent development but notable instability at the implementation level. DAV (Drug Administration of Vietnam) review capacity is still developing. Post-COVID backlog (2020–2022) has not been fully cleared. The regulatory framework references ASEAN/IMDRF but is substantially localized with complex requirements.

...